The primary efficacy outcome was a composite of CV death, myocardial infarction, stroke, systemic embolism, coronary revascularization, or acute limb ischemia. A total of 872 patients underwent randomization; 433 were assigned to the aspirin group, and 439 to the placebo group. The primary outcome was a composite of death, myocardial infarction, stroke, or repeat revascularization, evaluated at one year. A total of 2,201 patients were randomly assigned to receive ticagrelor plus aspirin (1,104 patients) or aspirin alone (1,097 patients). CVD risk predictionFive risk factors account for approximately 50 per cent of the global burden of CV disease (CVD).